Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition

Cancer Cell

Volumn 30, Issue 6, 2016, Pages 879-890

  Nakagawa, Shigeki ^a,b   Wei, Lan ^c   Song, Won Min ^a   Higashi, Takaaki ^a,b   Ghoshal, Sarani ^c   Kim, Rosa S ^a   Bian, C Billie ^a   Yamada, Suguru ^c   Sun, Xiaochen ^a   Venkatesh, Anu ^a   Goossens, Nicolas ^a,d   Bain, Gretchen ^e   Lauwers, Gregory Y ^f   Koh, Anna P ^a   El Abtah, Mohamed ^a   Ahmad, Noor B ^a   Hoshida, Hiroki ^a   Erstad, Derek J ^c   Gunasekaran, Ganesh ^a   Lee, Youngmin ^a   Yu, Ming Lung ^g,h   Chuang, Wan Long ^g   Dai, Chia Yen ^g   Kobayashi, Masahiro ⁱ   Kumada, Hiromitsu ⁱ   Beppu, Toru ^b   Baba, Hideo ^b   Mahajan, Milind ^a   Nair, Venugopalan D ^a   Lanuti, Michael ^c   Villanueva, Augusto ^a   Sangiovanni, Angelo ^j   Iavarone, Massimo ^j   Colombo, Massimo ^j   Llovet, Josep M ^a,k   Subramanian, Aravind ^l   Tager, Andrew M ^c   Friedman, Scott L ^a   Baumert, Thomas F ^c,m,n   Schwarz, Myron E ^a   Chung, Raymond T ^c   Tanabe, Kenneth K ^c   Zhang, Bin ^a   Fuchs, Bryan C ^c   Hoshida, Yujin ^a   more..

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b KUMAMOTO UNIVERSITY   (Japan)

^c HARVARD MEDICAL SCHOOL   (United States)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e PharmAkea Inc   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^h NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

ⁱ TORANOMON HOSPITAL   (Japan)

^j UNIVERSITY OF MILAN   (Italy)

^k UNIVERSITY OF BARCELONA   (Spain)

^l BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^m UNIVERSITÉ DE STRASBOURG   (France)

ⁿ HÔPITAL CIVIL   (France)

more..

Author keywords

cancer chemoprevention; gene signature; hepatocellular carcinoma; prognostic prediction; transcriptome

Indexed keywords

ALCOHOL; ALPHA SMOOTH MUSCLE ACTIN; C5 PROTEIN; CHEMOKINE RECEPTOR CXCR4; COL16A1 PROTEIN; COL6A3 PROTEIN; COLLAGEN TYPE 1; COMPLEMENT COMPONENT C8B; CONNECTIVE TISSUE GROWTH FACTOR; CTNND2 PROTEIN; EGF PROTEIN; EPHA4 PROTEIN; GLUTATHIONE PEROXIDASE 2; IGFBP6 PROTEIN; LOXL2 PROTEIN; LPP PROTEIN; LYSOPHOSPHATIDIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; NOS2A PROTEIN; PLG PROTEIN; PODXL PROTEIN; PROTEIN; PROTEIN KINASE B; PROTEIN P53; SCLEROPROTEIN; SECONDARY LYMPHOID TISSUE CHEMOKINE; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA; TTR PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; LYSOPHOSPHOLIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; FOLLOW UP; GENE EXPRESSION; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LIVER CANCER; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PREDICTION; PRIORITY JOURNAL; RAT; REGULATOR GENE; RNA SEQUENCE; SIGNAL TRANSDUCTION; STELLATE CELL; TRANSCRIPTOMICS; VIRAL CLEARANCE; ANIMAL; BIOSYNTHESIS; CARCINOMA, HEPATOCELLULAR; COMPLICATION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; GENETIC PREDISPOSITION; GENETICS; LIVER NEOPLASMS; PROCEDURES; RISK FACTOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LYSOPHOSPHOLIPIDS; RATS; RISK FACTORS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85003904956     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.11.004     Document Type: Article

References (42)

1. Agrawal, P., Yu, K., Salomon, A.R., Sedivy, J.M., Proteomic profiling of Myc-associated proteins. Cell Cycle 9 (2010), 4908–4921.
2. Berres, M.L., Koenen, R.R., Rueland, A., Zaldivar, M.M., Heinrichs, D., Sahin, H., Schmitz, P., Streetz, K.L., Berg, T., Gassler, N., et al. Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J. Clin. Invest. 120 (2010), 4129–4140.
3. Burra, P., Rodriguez-Castro, K.I., Neoplastic disease after liver transplantation: focus on de novo neoplasms. World J. Gastroenterol. 21 (2015), 8753–8768.
4. Calle, E.E., Rodriguez, C., Walker-Thurmond, K., Thun, M.J., Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 348 (2003), 1625–1638.
5. Calvisi, D.F., Ladu, S., Pinna, F., Frau, M., Tomasi, M.L., Sini, M., Simile, M.M., Bonelli, P., Muroni, M.R., Seddaiu, M.A., et al. SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis. Gastroenterology 137 (2009), 1816–1826.e1811–1810.
6. Chung, R.T., Baumert, T.F., Curing chronic hepatitis C–the arc of a medical triumph. N. Engl. J. Med. 370 (2014), 1576–1578.
7. Cooper, A.B., Wu, J., Lu, D., Maluccio, M.A., Is autotaxin (ENPP2) the link between hepatitis C and hepatocellular cancer?. J. Gastrointest. Surg. 11 (2007), 1628–1634 discussion 1634–5.
8. Cuzick, J., Sestak, I., Forbes, J.F., Dowsett, M., Knox, J., Cawthorn, S., Saunders, C., Roche, N., Mansel, R.E., von Minckwitz, G., et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 383 (2014), 1041–1048.
9. Davila, J.A., Morgan, R.O., Richardson, P.A., Du, X.L., McGlynn, K.A., El-Serag, H.B., Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 52 (2010), 132–141.
10. Fisher, R.A., Statistical Methods for Research Workers. 1932, Oliver and Boyd.
11. Forner, A., Llovet, J.M., Bruix, J., Hepatocellular carcinoma. Lancet 379 (2012), 1245–1255.
12. Franssen, B., Alshebeeb, K., Tabrizian, P., Marti, J., Pierobon, E.S., Lubezky, N., Roayaie, S., Florman, S., Schwartz, M.E., Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center. Ann. Surg. 260 (2014), 650–658.
13. Fuchs, B.C., Hoshida, Y., Fujii, T., Wei, L., Yamada, S., Lauwers, G.Y., McGinn, C.M., Deperalta, D.K., Chen, X., Kuroda, T., et al. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology 59 (2014), 1577–1590.
14. Gordon, S., Akopyan, G., Garban, H., Bonavida, B., Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 25 (2006), 1125–1142.
15. Hoshida, Y., Villanueva, A., Kobayashi, M., Peix, J., Chiang, D.Y., Camargo, A., Gupta, S., Moore, J., Wrobel, M.J., Lerner, J., et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 359 (2008), 1995–2004.
16. Hoshida, Y., Villanueva, A., Sangiovanni, A., Sole, M., Hur, C., Andersson, K.L., Chung, R.T., Gould, J., Kojima, K., Gupta, S., et al. Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology 144 (2013), 1024–1030.
17. Hoshida, Y., Fuchs, B.C., Bardeesy, N., Baumert, T.F., Chung, R.T., Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J. Hepatol. 61 (2014), S79–S90.
18. Huang, G., Brigstock, D.R., Regulation of hepatic stellate cells by connective tissue growth factor. Front Biosci. (Landmark Ed.) 17 (2012), 2495–2507.
19. Ishak, K., Baptista, A., Bianchi, L., Callea, F., De Groote, J., Gudat, F., Denk, H., Desmet, V., Korb, G., MacSween, R.N., et al. Histological grading and staging of chronic hepatitis. J. Hepatol. 22 (1995), 696–699.
20. Itzkowitz, S.H., Present, D.H., Crohn's and Colitis Foundation of America Colon Cancer in IBD Study Group. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm. Bowel Dis. 11 (2005), 314–321.
21. Kawada, N., Imanaka, K., Kawaguchi, T., Tamai, C., Ishihara, R., Matsunaga, T., Gotoh, K., Yamada, T., Tomita, Y., Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J. Gastroenterol. 44 (2009), 1190–1194.
22. Kihara, Y., Mizuno, H., Chun, J., Lysophospholipid receptors in drug discovery. Exp. Cell Res. 333 (2015), 171–177.
23. King, L.Y., Canasto-Chibuque, C., Johnson, K.B., Yip, S., Chen, X., Kojima, K., Deshmukh, M., Venkatesh, A., Tan, P.S., Sun, X., et al. A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut 64 (2015), 1296–1302.
24. Lippman, S.M., Klein, E.A., Goodman, P.J., Lucia, M.S., Thompson, I.M., Ford, L.G., Parnes, H.L., Minasian, L.M., Gaziano, J.M., Hartline, J.A., et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301 (2009), 39–51.
25. Mehal, W.Z., Schuppan, D., Antifibrotic therapies in the liver. Semin. Liver Dis. 35 (2015), 184–198.
26. Minami, T., Tateishi, R., Shiina, S., Nakagomi, R., Kondo, M., Fujiwara, N., Mikami, S., Sato, M., Uchino, K., Enooku, K., et al. Comparison of improved prognosis between hepatitis B- and hepatitis C-related hepatocellular carcinoma. Hepatol. Res. 45 (2015), E99–E107.
27. Morgan, R.L., Baack, B., Smith, B.D., Yartel, A., Pitasi, M., Falck-Ytter, Y., Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann. Intern. Med. 158 (2013), 329–337.
28. Muir, K., Hazim, A., He, Y., Peyressatre, M., Kim, D.Y., Song, X., Beretta, L., Proteomic and lipidomic signatures of lipid metabolism in NASH-associated hepatocellular carcinoma. Cancer Res. 73 (2013), 4722–4731.
29. Nakagawa, H., Ikeda, H., Nakamura, K., Ohkawa, R., Masuzaki, R., Tateishi, R., Yoshida, H., Watanabe, N., Tejima, K., Kume, Y., et al. Autotaxin as a novel serum marker of liver fibrosis. Clin. Chim. Acta 412 (2011), 1201–1206.
30. Pradere, J.P., Klein, J., Gres, S., Guigne, C., Neau, E., Valet, P., Calise, D., Chun, J., Bascands, J.L., Saulnier-Blache, J.S., Schanstra, J.P., LPA1 receptor activation promotes renal interstitial fibrosis. J. Am. Soc. Nephrol. 18 (2007), 3110–3118.
31. Sakai, N., Chun, J., Duffield, J.S., Wada, T., Luster, A.D., Tager, A.M., LPA1-induced cytoskeleton reorganization drives fibrosis through CTGF-dependent fibroblast proliferation. FASEB J. 27 (2013), 1830–1846.
32. Saville, M.K., Sparks, A., Xirodimas, D.P., Wardrop, J., Stevenson, L.F., Bourdon, J.C., Woods, Y.L., Lane, D.P., Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C in vivo. J. Biol. Chem. 279 (2004), 42169–42181.
33. Song, W.M., Zhang, B., Multiscale embedded gene Co-expression network analysis. PLoS Comput. Biol., 11, 2015, e1004574.
34. Stein, A.J., Bain, G., Prodanovich, P., Santini, A.M., Darlington, J., Stelzer, N.M., Sidhu, R.S., Schaub, J., Goulet, L., Lonergan, D., et al. Structural basis for inhibition of human autotaxin by four potent compounds with distinct modes of binding. Mol. Pharmacol. 88 (2015), 982–992.
35. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., Mesirov, J.P., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102 (2005), 15545–15550.
36. Swaney, J.S., Chapman, C., Correa, L.D., Stebbins, K.J., Broadhead, A.R., Bain, G., Santini, A.M., Darlington, J., King, C.D., Baccei, C.S., et al. Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. J. Pharmacol. Exp. Ther. 336 (2011), 693–700.
37. Tager, A.M., LaCamera, P., Shea, B.S., Campanella, G.S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B.A., Kim, N.D., et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat. Med. 14 (2008), 45–54.
38. van der Meer, A.J., Veldt, B.J., Feld, J.J., Wedemeyer, H., Dufour, J.F., Lammert, F., Duarte-Rojo, A., Heathcote, E.J., Manns, M.P., Kuske, L., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308 (2012), 2584–2593.
39. Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A. Jr., Kinzler, K.W., Cancer genome landscapes. Science 339 (2013), 1546–1558.
40. Watanabe, N., Ikeda, H., Nakamura, K., Ohkawa, R., Kume, Y., Aoki, J., Hama, K., Okudaira, S., Tanaka, M., Tomiya, T., et al. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J. Clin. Gastroenterol. 41 (2007), 616–623.
41. Zhang, Y.J., Li, H., Wu, H.C., Shen, J., Wang, L., Yu, M.W., Lee, P.H., Bernard Weinstein, I., Santella, R.M., Silencing of Hint1, a novel tumor suppressor gene, by promoter hypermethylation in hepatocellular carcinoma. Cancer Lett. 275 (2009), 277–284.
42. Zhang, D.Y., Goossens, N., Guo, J., Tsai, M.C., Chou, H.I., Altunkaynak, C., Sangiovanni, A., Iavarone, M., Colombo, M., Kobayashi, M., et al. A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. Gut 65 (2016), 1754–1764.